At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ADGI Adagio Therapeutics
Closed 09-12 16:00:00 EDT
4.64
+0.00
0.00%
High4.64
Low4.64
Vol0.00
Open4.64
D1 Closing4.64
Amplitude0.00%
Mkt Cap504.97M
Tradable Cap204.70M
Total Shares108.83M
T/O2.47M
T/O Rate0.00%
Tradable Shares44.12M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Adagio Therapeutics changes name to Invivyd, generates COVID-19 antibodies
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. Its lead product candidate is the ADG20, a neutralizing antibody that is in Phase II/III clinical trials for the treatment and prevention of coronavirus disease. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. Adagio Therapeutics, Inc. was incorporated in 2020 and is based in Waltham, Massachusetts.